Human IFN-γ T cell ELISPOT kit - 2-plate

SKU

CT230-B2

All-inclusive ELISPOT kit with reagents and plates (192 determinations).

Format

2-plate

Price

€ 485

Documentation

Data sheet

Manual

SDS

Reactivity

Human

Category

T cell ELISPOT

Analyte

IFN-γ

Description

Our ELISPOT kits provide a complete, ready-to-use solution for reliable, high-performance ELISPOT assays. Each kit includes all essential components: coating and detection antibodies, streptavidin-HRP, TMB substrate, blocking stock solution, dilution buffer, Tween-20, and high-quality PVDF ELISPOT plates with lids and adhesive plate covers.

Analyte information

Description

IFN-γ is a potent immune regulating cytokine that plays a central role in activating the body’s defense against infections and malignant cells. By enhancing antigen presentation and boosting the activity of T cells and natural killer (NK) cells, IFN-γ drives strong antiviral and anti tumor responses. It is primarily produced by activated T helper 1 (Th1) cells, cytotoxic T cells, γδ T cells, NK cells, and natural killer T (NKT) cells, making it a key indicator of cellular immune activation in research and diagnostic applications.

Alternative names

IFN-γ, IFN-gamma, IFN-g, IFNg, interferon γ, interferon-γ, interferon-gamma, interferon gamma, INF-g, INF-gamma, immune interferon, Type II interferon

Gene ID

3458

References

Authors, et al.	Title	Journal	Year	Volume	Pages
Naglaa Shoukry	Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection	J Exp Med	2003	197	1645-55
Nicole van Besouw	The frequency of interferon-gproducing cells reflects alloreactivity against minor histocompatibility antigens	Transplantation	2003	75	1400-4
N van Besouw	Anti-CD25 therapy impairs donor-specific Th1 and Th2 cytokine-producing peripheral blood cells after clinical heart transplantation	Transplant Proc	2002	34	2942-3
Astrid van Halteren	Redirection of human autoreactive T-cells Upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D(3)	Diabetes	2002	51	2119-25
S Schmid	Reduced IL-4 associated antibody responses to vaccine in early pre-diabetes	Diabetologia	2002	45	677-85
I Raz	Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial	Lancet	2001	358	1749-53
S Martin	Development of type 1 diabetes despite severe hereditary B-cell deficiency	N Engl J Med	2001	345	1036-40

Authors, et al.

Title

Journal

Year

Volume

Pages

Naglaa Shoukry

Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection

J Exp Med

2003

197

1645-55

Nicole van Besouw

The frequency of interferon-gproducing cells reflects alloreactivity against minor histocompatibility antigens

Transplantation

2003

1400-4

N van Besouw

Anti-CD25 therapy impairs donor-specific Th1 and Th2 cytokine-producing peripheral blood cells after clinical heart transplantation

Transplant Proc

2002

2942-3

Astrid van Halteren

Redirection of human autoreactive T-cells Upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D(3)

Diabetes

2002

2119-25

S Schmid

Reduced IL-4 associated antibody responses to vaccine in early pre-diabetes

Diabetologia

2002

677-85

I Raz

Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial

Lancet

2001

358

1749-53

S Martin

Development of type 1 diabetes despite severe hereditary B-cell deficiency

N Engl J Med

2001

345

1036-40